Andere Sprachen Tiziana Life Sciences Ltd

Aktien

A3C5SS

BMG889121031

TLSA

Verzögert Nasdaq Andere Börsenplätze 17:36:05 07.06.2024			% 5 Tage	% 1. Jan.
0,9761 ^USD	-2,39 %		-2,38 %	+74,30 %

06.06.	Foralumab von Tiziana Life Sciences zeigt qualitative Verbesserung bei Multiple-Sklerose-Patienten nach 6-monatiger Anwendung	MT
06.06.	Tiziana Life Sciences, Ltd. gibt die qualitativen Ergebnisse für alle 10 nicht aktiven Patienten mit sekundär progredienter Multipler Sklerose (na-SpMS) bekannt, die in das Expanded Access (Ea) Programm für Patienten mittlerer Größe aufgenommen wurden	CI

Andere Sprachen

Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!

100% kostenlose Registrierung

Tiziana Life Sciences' Foralumab Demonstrates Qualitative Improvement in Multiple Sclerosis Patients After 6 Months Use	06.06.
Tiziana Life Sciences Announces Six-Month Qualitative Improvement in Neuroimaging in 80% of Multiple Sclerosis Patients Receiving Intranasal Foralumab	06.06.
Tiziana Life Sciences, Ltd. Announces Qualitative Results for All 10 Non-Active Secondary Progressive Multiple Sclerosis (Na-Spms) Patients Enrolled in the Intermediate-Size Patient Population Expanded Access (Ea) Program	06.06.
Tiziana Life Sciences Submits Grant Application to ALS Association to Fund Clinical Trial of Intranasal Foralumab	04.06.
Tiziana Life Sciences Scientific Board Chairman to Receive Prestigious Award for Multiple Sclerosis Research	30.05.
Tiziana Life Sciences Files for Orphan Drug Designation for Intranasal Foralumab	13.05.
Tiziana Life Sciences Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	10.05.
MEDIA: MS News Today: Foralumab found to ease fatigue in SPMS patients in access program	25.04.
Tiziana Life Sciences Reports Positive 3-Month Neuroimaging Scores in Multiple Sclerosis Patients Receiving Intranasal Foralumab	25.04.
Tiziana Life Sciences Ltd Reports Positive 3-Month Neuroimaging Scores in Multiple Sclerosis Patients Receiving Intranasal Foralumab	25.04.
Sector Update: Health Care Stocks Rise in Afternoon Trading	23.04.
Tiziana Life Sciences Says US FDA Allows Enrollment of 20 More Patients in Foralumab MS Expanded Access Program	23.04.
Tiziana Life Sciences Announces FDA Allowance for Additional Twenty Patients to be Enrolled in the Intranasal Foralumab Multiple Sclerosis Expanded Access Program	23.04.
Tiziana Life Sciences, Ltd. Announces FDA Allowance for Additional Twenty Patients to Be Enroll in Intranasal Foralumab Multiple Sclerosis Expanded Access Program	23.04.
Tiziana Life Sciences Announces Study Results from Intranasal Anti-CD3 Foralumab in Multiple Sclerosis Patients with PIRA Highlighted in Neurology Today	22.04.
Tiziana Life Sciences Announces Additional Clinical Improvements Among Multiple Sclerosis Patients in its Expanded Access Program	22.04.
Tiziana Life Sciences Announces Additional Clinical Improvements Among Multiple Sclerosis Patients in Its Expanded Access Program	22.04.
Tiziana Life Sciences Announces New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of Neurology	19.04.
Tiziana Life Sciences Announces Study Results from Intranasal Anti-CD3 Foralumab in Multiple Sclerosis Patients with PIRA Highlighted in Neurology Today®	19.04.
Tiziana Life Sciences Announces Study Results from Intranasal Anti-CD3 Foralumab in Multiple Sclerosis Patients with Pira Highlighted in Neurology	19.04.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Tiziana Life Sciences Ltd

Aktien

A3C5SS

BMG889121031

TLSA

Andere Sprachen

Filter